Companion diagnostics (CDx) plays a pivotal role in precision medicine by enabling personalized treatment plans based on individual biomarker profiles. This approach can enhance therapeutic efficacy in selected indications and may reduce healthcare expenditures. Particularly in oncology, precision targeted therapies targeting pathways such as EGFR, HER2, and programmed death-1/programmed death-ligand 1 have established robust models for biomarker-driven treatment. However, rapid advancements in diagnostic technologies, expanding application scopes, and increasingly complex mechanisms of biomarker resistance are presenting new challenges for CDx. This review comprehensively examines the evolving regulatory landscape, current clinical applications across various solid tumors and hematologic malignancies, and diverse methodological platforms ranging from next-generation sequencing and immunohistochemistry to emerging liquid biopsies and point-of-care testing. It also delves into persistent barriers in CDx development, including tumor heterogeneity, test standardization, trade-offs between tissue biopsy and liquid biopsy, and the economic complexities of codevelopment and reimbursement mechanisms. By synthesizing existing knowledge and projecting future trends, this paper serves as a valuable resource for researchers, regulators, and clinicians. It provides critical insights to guide the synergistic development of drugs and diagnostics, paving the way for their integration into a more dynamic, artificial intelligence-enhanced, and multiomics-driven healthcare ecosystem.
Wu et al. (Sun,) studied this question.